Type 2 diabetes mellitus
Conditions
Interventions
Coagliptin group:Treated with codagliptin
Sponsors
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Can understand and voluntarily sign the written informed consent form; 2.Age >=18 years old; 3.Patients met the criteria for recurrence after remission of type 2 diabetes mellitus, i.e., glycosylated hemoglobin (HbA1c) could not be maintained <6.5% after stopping glucose-lowering drugs for at least 3 months; and HbA1c<8.5%; 4.Coogliptin monotherapy was required, as judged by the investigator;
Exclusion criteria
Exclusion criteria: 1.Participated in any other clinical study within 30 days before screening; 2.Patients with severe organ dysfunction or malignant tumor of the heart, liver, kidney, etc; 3.Pregnant or lactating women; 4.Allergy to coagliptin or other drug components used in this study; 5.Persons with severe mental illness or cognitive impairment; 6.There were other conditions deemed by the investigator to be inappropriate for participation in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycated hemoglobin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Two hours postprandial blood glucose;Fasting blood glucose;Blood insulin;Fasting C-peptide;Adverse events during the treatment period;Two hours postprandial C-peptide; | — |
Countries
China
Contacts
Public ContactShao Shiying
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Outcome results
None listed